The estimated Net Worth of Seah H. Lim is at least $93.4 mil dollars as of 20 December 2023. Seah Lim owns over 32,500 units of Emmaus Life Sciences Incorporation stock worth over $91,733 and over the last 2 years Seah sold EMMA stock worth over $1,625.
Sign up
Seah Lim EMMA stock SEC Form 4 insiders trading
Seah has made over 2 trades of the Emmaus Life Sciences Incorporation stock since 2022, according to the Form 4 filled with the SEC. Most recently Seah sold 32,500 units of EMMA stock worth $1,625 on 20 December 2023.
The largest trade Seah's ever made was buying 139,200 units of Emmaus Life Sciences Incorporation stock on 9 October 2022 worth over $30,624. On average, Seah trades about 42,925 units every 109 days since 2022. As of 20 December 2023 Seah still owns at least 4,586,626 units of Emmaus Life Sciences Incorporation stock.
You can see the complete history of Seah Lim stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Seah Lim's mailing address?
Seah's mailing address filed with the SEC is 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE, CA, 90503.
Insiders trading at Emmaus Life Sciences Incorporation
Over the last 5 years, insiders at Emmaus Life Sciences Incorporation have traded over $1,625 worth of Emmaus Life Sciences Incorporation stock and bought 2,618,727 units worth $3,075,792 . The most active insiders traders include Yutaka Niihara, Willis C Lee, eSeah H. Lim. On average, Emmaus Life Sciences Incorporation executives and independent directors trade stock every 10 days with the average trade being worth of $325. The most recent stock trade was executed by Willis C Lee on 26 February 2024, trading 115,200 units of EMMA stock currently worth $14,976.
What does Emmaus Life Sciences Incorporation do?
emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.
What does Emmaus Life Sciences Incorporation's logo look like?
Complete history of Seah Lim stock trades at Emmaus Life Sciences Incorporation
Emmaus Life Sciences Incorporation executives and stock owners
Emmaus Life Sciences Incorporation executives and other stock owners filed with the SEC include:
-
Dr. Yutaka Niihara M.D., M.P.H, M.P.H.,
Chairman & CEO -
Yasushi Nagasaki CPA, CPA,
Chief Financial Officer -
Willis C. Lee M.S.,
Vice Chairman & COO -
Ian Zwicker,
Director -
Wei Peu Zen,
Director -
Jane Wood,
Director -
Masaharu Osato,
Director -
Robert Dickey,
Director -
Yasushi Nagasaki,
Interim Chief Financial Officer -
Willis Lee,
Vice Chairman of the Board, Chief Operating Officer -
Lan Tran,
President, Chief Administrative Officer -
Yutaka Niihara,
Chairman of the Board, Chief Executive Officer -
S. Steven Lee,
Independent Consultant -
Kurt H. Kruger M.B.A., M.S.,
Consultant -
Dr. Charles W. Stark Pharm.D., Pharm.D,
Sr. VP of Medical Affairs, Clinical, Regulatory -
Dale E. Short J.D.,
Gen. Counsel -
George Sekulich,
Sr. VP of Global Commercialization & Chief Information Officer -
Charles William Stark,
CSO & EVP Clinical Development -
Seah H. Lim,
Director -
Alfred Fu Kong Lui,
Director -
George Sekulich,
Co-President & CCO